Interleukin-2: all 213 studies that test it
Page 2 of 3. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.
- Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus InfectionStatus unknownNCT04225780Phase 1/2
- Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for MelanomaCompletedNCT04165967Phase 1
- Low-dose Recombinant Human IL-2 for the Treatment of Relapsing PolychondritisCompletedNCT04077736Phase 2
- Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled TrialCompletedNCT04077684Phase 2
- Low-dose IL-2 Treatment on Behcet's DiseaseCompletedNCT04065672Phase 2
- Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory MyopathyStatus unknownNCT04062019Phase 2
- Low-dose Interleukin-2 Treatment on Polymyalgia RheumaticaStatus unknownNCT04062006Phase 2
- Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus VulgarisStatus unknownNCT04023149Phase 2
- Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid TumorsTerminatedNCT03992326Phase 1
- Low-dose Interleukin-2 in Women With Unexplained MiscarriagesCompletedNCT03970954Phase 1/2
- The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic MelanomaWithdrawnNCT03928275Phase 2/3
- TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)CompletedNCT03475134Phase 1
- Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic OvarianStatus unknownNCT03412526Phase 2
- Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2CompletedNCT03346499Phase 1
- Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2
- Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCATerminatedNCT03241719Early Phase 1
- Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCCWithdrawnNCT03226236Phase 2
- Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRCWithdrawnNCT03222089Phase 2
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal IntCompletedNCT03213964Phase 1
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCCStatus unknownNCT03175705Phase 1
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2
- Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of ChimerismStatus unknownNCT03101423Not applicable
- Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell MalignanciesWithdrawnNCT03098355Phase 1/2
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
- MIROCALS: Modifying Immune Response and OutComes in ALSCompletedNCT03039673Phase 2
- Low-dose IL-2 for Treg Expansion and Tolerance (LITE)TerminatedNCT02949492Phase 4
- Anti-infection of Low-does IL-2 in SLECompletedNCT02932137Not applicable
- Response-based Treatment of High-risk NeuroblastomaStatus unknownNCT02771743Phase 2
- NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/AdolescentsCompletedNCT02763475Phase 2
- T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive SystemStatus unknownNCT02662348Phase 1
- Prophylaxis Roles of IL-2 Treatment on GVHD After TransplantationStatus unknownNCT02659657Phase 2
- NB2013-HR German (GPOH) / Dutch (DCOG) TrialTerminatedNCT02641782Phase 2
- Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
- Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）Status unknownNCT02569463Phase 1/2
- TREg Activation in the Treatment of the PELADE (Alopecia Areata)CompletedNCT02557074Phase 3
- A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus ErythematosusStatus unknownNCT02465580Phase 2
- A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's SyndromeCompletedNCT02464319Phase 2
- Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple SclerosisCompletedNCT02424396Phase 2
- TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma PatientsCompletedNCT02414945Phase 1/2
- Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional TreatmentTerminatedNCT02389231Phase 1/2
- Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B PatientsCompletedNCT02360592Phase 4
- Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHDCompletedNCT02318082Phase 1
- Intermittent ART in Primary HIV InfectionCompletedNCT02300623Phase 4
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
- Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and OsteosarcomaStatus unknownNCT02173093Phase 1/2
- TIL Therapy in Metastatic Melanoma and IL2 Dose AssessmentTerminatedNCT01995344Phase 2
- Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory DiseasesCompletedNCT01988506Phase 2
- Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseActive, not recruitingNCT01937468Phase 1
- Mother-caregivers of Children With Duchenne Muscular DystrophyCompletedNCT01921374Not applicable
- Withdrawal of Immunosuppression in Recipients of Face and Extremity TransplantsCompletedNCT01853111Phase 1
- Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia AreataTerminatedNCT01840046Phase 1/2
- Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic MelanomaWithdrawnNCT01833767Phase 2
- NY-ESO-1 T Cells in OG CancerTerminatedNCT01795976Phase 2
- Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric CancerCompletedNCT01671774Phase 1
- Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorCompletedNCT01603212Phase 1
- Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After TransplantationTerminatedNCT01517347Not applicable
- A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2CompletedNCT01480323Phase 2
- A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT01462903Phase 1
- IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic MelanomaWithdrawnNCT01409187Phase 1/2
- IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
- Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney CancerWithdrawnNCT01355562Phase 2
- Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid LeukemiaCompletedNCT01347996Phase 4
- Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic SyndromesWithdrawnNCT01324960Phase 1/2
- Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal CancerCompletedNCT01176552Phase 2
- Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic MelanomaCompletedNCT00970996Phase 1
- CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid MalignanciesCompletedNCT00968760Phase 1
- T-cell Based Immunotherapy for of MelanomaCompletedNCT00937625Phase 1/2
- Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk MelanomaCompletedNCT00928902Phase 2
- Interleukin-2 Treatment for Wiskott-Aldrich SyndromeCompletedNCT00774358Phase 1
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesCompletedNCT00697671Phase 1
- Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)CompletedNCT00609401Phase 2
- Proleukin and Rapamune in Type 1 DiabetesCompletedNCT00525889Phase 1
- Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.CompletedNCT00502034Phase 3
- Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV MelanomaCompletedNCT00470015Phase 1
- Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2Status unknownNCT00451984Phase 3
- Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney CancerTerminatedNCT00440973Phase 2
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaActive, not recruitingNCT00338377Phase 2
- Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic CancerCompletedNCT00329368Phase 1
- Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell CarcinomaCompletedNCT00325507Phase 2
- Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate PrognosisCompletedNCT00291369Phase 3
- Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate CancerCompletedNCT00283829Phase 1/2
- Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype ITerminatedNCT00277758Phase 1
- Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor CellsWithdrawnNCT00224354Phase 1
- Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma MetastasesCompletedNCT00204581Phase 2
- Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell CarcinomaTerminatedNCT00203866Phase 2
- HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary InfectionTerminatedNCT00196651Phase 2
- Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory NeuroblastomaCompletedNCT00186862Phase 1
- Tumor-Pulsed Dendritic Cells Used as a Tumor VaccineTerminatedNCT00176761Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)CompletedNCT00120185Phase 2
- Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)CompletedNCT00113282Phase 2
- Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell CancerCompletedNCT00100906Phase 2
- Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00100737Phase 2
- Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerTerminatedNCT00091611Phase 1
- A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell CancerCompletedNCT00083941Phase 2
- Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedNCT00080353Phase 2
- Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIVCompletedNCT00056797Phase 2
- Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2CompletedNCT00050726Phase 2
- Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsCompletedNCT00045877Phase 2/3
- Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.CompletedNCT00045864Phase 2